KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Edwards Lifesciences (EW) Long-Term Debt Issuances (2016 - 2021)

Edwards Lifesciences has reported Long-Term Debt Issuances over the past 11 years, most recently at -$8.8 million for Q3 2021.

  • For Q3 2021, Long-Term Debt Issuances fell 617.65% year-over-year to -$8.8 million; the TTM value through Jun 2022 reached -$8.8 million, down 144.9%, while the annual FY2021 figure was $5.2 million, 67.9% down from the prior year.
  • Long-Term Debt Issuances for Q3 2021 was -$8.8 million at Edwards Lifesciences, down from $9.5 million in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $608.0 million in Q2 2017 and troughed at -$8.8 million in Q3 2021.
  • A 5-year average of $86.4 million and a median of $4.5 million in 2021 define the central range for Long-Term Debt Issuances.
  • Biggest five-year swings in Long-Term Debt Issuances: surged 9706.45% in 2017 and later tumbled 617.65% in 2021.
  • Year by year, Long-Term Debt Issuances stood at $5.4 million in 2017, then tumbled by 70.37% to $1.6 million in 2018, then skyrocketed by 331.25% to $6.9 million in 2019, then plummeted by 43.48% to $3.9 million in 2020, then tumbled by 325.64% to -$8.8 million in 2021.
  • Business Quant data shows Long-Term Debt Issuances for EW at -$8.8 million in Q3 2021, $9.5 million in Q2 2021, and $4.5 million in Q1 2021.